Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 1.015
1.
Article En | MEDLINE | ID: mdl-38031151

OBJECTIVE: This study aimed to examine infantile outcomes at 3 years of age with selective fetal growth restriction (sFGR) Types II and III with isolated oligohydramnios who underwent fetoscopic laser photocoagulation (FLP). METHODS: This multicenter prospective cohort study included monochorionic diamniotic twins who underwent FLP for sFGR between 16 and 25 weeks of gestation. The indication for performing FLP was in cases of sFGR Type II or III with oligohydramnios, where the maximal vertical pocket was ≤2 cm among twins with FGR. This was done in the absence of a typical twin-twin transfusion syndrome diagnosis. The primary outcome was the intact survival (IS) rate of infants at the corrected age of 40 weeks and 3 years. IS at the corrected age of 40 weeks was defined as survival without grade III or IV intraventricular hemorrhage or cystic periventricular leukomalacia, and IS at 3 years of age was defined as survival without neurodevelopmental morbidity, including cerebral palsy, neurodevelopmental impairment with a total developmental quotient of ≤70, bilateral deafness, or bilateral blindness. RESULTS: Among 45 patients with sFGR, 30 (66.7%) were classified as having Type II and 15 (33.3%) as Type III sFGR. The prevalence of IS at the corrected age of 40 weeks was 51.1% (n=23) in FGR twins and 95.5% (n=42) in larger twins. The prevalence of IS at 3 years of age was 46.7% (n=21) in FGR twins and 86.4% (n=38) in larger twins. Among the 24 FGR twins who were not diagnosed with IS at 3 years of age, 91.7% (22 of 24 cases) suffered fetal or infantile demise other than miscarriage and neurodevelopmental impairment. All larger twins who were not diagnosed with IS at 3 years of age (n=6, 13.6%) had neurological morbidity, in addition to one case of miscarriage. CONCLUSIONS: FGR twins and larger twins, when subjected to FLP due to sFGR coupled with umbilical artery Doppler abnormalities and isolated oligohydramnios, exhibit low rates of neurological morbidity and low mortality, respectively. Therefore, FLP for Type II or III sFGR with oligohydramnios may be a feasible and preferable management option. This article is protected by copyright. All rights reserved.

2.
J Colloid Interface Sci ; 642: 227-234, 2023 Jul 15.
Article En | MEDLINE | ID: mdl-37004257

HYPOTHESIS: Horseshoe vortices are known to emerge around large-scale obstacles, such as bridge pillars, due to an inertia-driven adverse pressure gradient forming on the upstream-side of the obstacle. We contend that a similar flow structure can arise in thin-film Stokes flow around micro-obstacles, such as used in textured surfaces to improve wettability. This could be exploited to enhance mixing in microfluidic devices, typically limited to creeping-flow regimes. EXPERIMENTS: Numerical simulations based on the Navier-Stokes equations are carried out to elucidate the flow structure associated with the wetting dynamics of a liquid film spreading around a 50 µm diameter micro-pillar. The employed multiphase solver, which is based on the volume of fluid method, accurately reproduces the wetting dynamics observed in current and previous (Mu et al., Langmuir, 2019) experiments. FINDINGS: The flow structure within the liquid meniscus forming at the foot of the micro-pillar evinces a horseshoe vortex wrapping around the obstacle, notwithstanding that the Reynolds number in our system is extremely low. Here, the adverse pressure gradient driving flow reversal near the bounding wall is caused by capillarity instead of inertia. The horseshoe vortex is entangled with other vortical structures, leading to an intricate flow system with high-potential mixing capabilities.

3.
Phys Rev Lett ; 124(20): 202501, 2020 May 22.
Article En | MEDLINE | ID: mdl-32501086

We measured missing mass spectrum of the ^{12}C(γ,p) reaction for the first time in coincidence with potential decay products from η^{'} bound nuclei. We tagged an (η+p) pair associated with the η^{'}N→ηN process in a nucleus. After applying kinematical selections to reduce backgrounds, no signal events were observed in the bound-state region. An upper limit of the signal cross section in the opening angle cosθ_{lab}^{ηp}<-0.9 was obtained to be 2.2 nb/sr at the 90% confidence level. It is compared with theoretical cross sections, whose normalization ambiguity is suppressed by measuring a quasifree η^{'} production rate. Our results indicate a small branching fraction of the η^{'}N→ηN process and/or a shallow η^{'}-nucleus potential.

5.
Ultrasound Obstet Gynecol ; 55(4): 516-522, 2020 04.
Article En | MEDLINE | ID: mdl-30989734

OBJECTIVE: EXTrauterine Environment for Neonatal Development (EXTEND) is a system to support ongoing fetal growth and organ development in an extrauterine environment, utilizing a pumpless low-resistance oxygenator circuit. The aim of this study was to evaluate hemodynamics and cardiac function in fetal sheep sustained on the EXTEND system. METHODS: This was a prospective study of fetal sheep supported for a minimum of 3 weeks on EXTEND. Hemodynamic parameters were assessed weekly and included heart rate, mean arterial pressure (MAP), Doppler-echocardiography-derived cardiac output (CO), pulsatility indices (PIs) of the fetal middle cerebral artery (MCA), umbilical artery (UA) and ductus venosus and cardiac function, as assessed by speckle-tracking-derived global longitudinal strain and strain rate in the right (RV) and left (LV) ventricles. Parameters were compared at 0 days and 1, 2 and 3 weeks following placement on EXTEND. RESULTS: Of 10 fetal sheep enrolled, seven survived for 3 weeks and were included in the analysis. Median gestational age at cannulation was 107 (range, 95-109) days. Heart rate decreased and MAP increased significantly, but within acceptable ranges, during the study period. The quantities and relative ratios of right and left CO remained stable within the anticipated physiological range throughout the study period. Vascular tracings and PIs appeared to be similar to those seen normally in the natural in-utero state, with MCA-PI being higher than UA-PI. UA tracings demonstrated maintained abundant diastolic flow despite the absence of placental circulation. In both the RV and LV, strain decreased significantly at 1 and 2 weeks relative to baseline but returned to baseline values by week 3. CONCLUSIONS: The EXTEND mechanical support system replicates natural physiology and creates a stable and sustainable cardiovascular construct that supports growth over a 3-week period. However, there is a period of depressed contractility within the first week with subsequent improvement by week 3. This may reflect a period of physiological accommodation that warrants further investigation. This study lays the foundation for further exploration as the EXTEND system moves towards human application. © 2019 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.


Cardiotocography/methods , Echocardiography, Doppler/methods , Extracorporeal Membrane Oxygenation , Fetal Heart/diagnostic imaging , Fetus/diagnostic imaging , Animals , Animals, Newborn/embryology , Animals, Newborn/growth & development , Cardiac Output , Female , Fetal Development/physiology , Fetal Heart/embryology , Fetal Heart/growth & development , Fetus/embryology , Fetus/physiopathology , Heart Ventricles/diagnostic imaging , Hemodynamics , Middle Cerebral Artery/embryology , Pregnancy , Prospective Studies , Pulsatile Flow , Sheep , Time Factors , Umbilical Arteries/embryology
6.
Blood Cancer J ; 7(9): e601, 2017 09 01.
Article En | MEDLINE | ID: mdl-28862699

Although the introduction of tyrosine kinase inhibitors (TKIs) has improved overall survival of patients with chronic myeloid leukemia (CML), about half of the patients eventually relapse after cessation of TKIs. In contrast, the remainder of the patients maintain molecular remission without TKIs, indicating that the patients' immune system could control proliferation of TKI-resistant leukemic stem cells (LSCs). However, the precise mechanism of immunity against CML-LSCs is not fully understood. We have identified a novel immune target, CXorf48, expressed in LSCs of CML patients. Cytotoxic T cells (CTLs) induced by the epitope peptide derived from CXorf48 recognized CD34+CD38- cells obtained from the bone marrow of CML patients. We detected CXorf48-specific CTLs in the peripheral blood mononuclear cells from CML patients who have discontinued imatinib after maintaining complete molecular remission for more than 2 years. Significantly, the relapse rate of CXorf48-specific CTL-negative patients was 63.6%, compared to 0% in CXorf48-specific CTL-positive patients. These results indicate that CXorf48 could be a promising therapeutic target of LSCs for immunotherapy to obtain durable treatment-free remission in CML patients.


Bone Marrow Cells/immunology , CD8-Positive T-Lymphocytes/immunology , Gene Expression Regulation, Leukemic/immunology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/immunology , Neoplasm Proteins/immunology , Neoplastic Stem Cells/immunology , Bone Marrow Cells/pathology , CD8-Positive T-Lymphocytes/pathology , Female , Gene Expression Regulation, Leukemic/drug effects , Humans , K562 Cells , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Male , Neoplastic Stem Cells/pathology , THP-1 Cells
7.
J Phys Condens Matter ; 29(5): 055002, 2017 Feb 08.
Article En | MEDLINE | ID: mdl-27911879

An interface electron state at the junction between a three-dimensional topological insulator film, Bi2Se3, and a ferrimagnetic insulator film, Y3Fe5O12 (YIG), was investigated by measurements of angle-resolved photoelectron spectroscopy and x-ray absorption magnetic circular dichroism. The surface state of the Bi2Se3 film was directly observed and localized 3d spin states of the Fe3+ in the YIG film were confirmed. The proximity effect is likely described in terms of the exchange interaction between the localized Fe 3d electrons in the YIG film and delocalized electrons of the surface and bulk states in the Bi2Se3 film.

8.
Int J Obes (Lond) ; 40(3): 425-33, 2016 Mar.
Article En | MEDLINE | ID: mdl-26435324

BACKGROUND: Obesity and metabolic syndrome are the major risk factors for cardiovascular disease. Obesity is caused by increased food intake and/or decreased energy expenditure. Leptin potently inhibits food intake and promotes energy expenditure. These effects of leptin involve the activation of proopiomelanocortin (POMC) neurons in the hypothalamus arcuate nucleus (ARC). Disruption of leptin signaling in POMC neuron is considered one of the major causes for obesity. AIMS: The present study aimed to examine whether overexpression of interleukin-10 (IL-10) could substitute for the leptin action and ameliorate obesity in leptin-deficient Lep(ob/ob) mice. DESIGN: Adeno-associated virus (AAV) expressing murine IL-10 (AAV-mIL-10) was injected into the skeletal muscle to overexpress IL-10 in mice. These mice were subsequently subjected to analysis of body weight, food intake, glucose metabolism and underlying mechanisms. RESULTS: In Lep(ob/ob) mice, AAV-IL-10 ameliorated hyperphagia, obesity, glucose intolerance and insulin resistance, as well as attenuated tumor necrosis factor-α expression. The IL-10 treatment also improved glucose-induced insulin release. Furthermore, IL-10 treatment increased POMC mRNA expression in ARC and phosphorylation of signal transducer and activator of transcription-3 (STAT3) in ARC and white adipose tissue (WAT). In neuron-specific STAT3-null mice that exhibited obesity and hyperphagia, AAV-mIL-10 administration failed to affect food intake, body weight and phosphorylation of STAT3 in WAT. CONCLUSIONS: These results demonstrate that peripheral overexpression of IL-10 induces STAT3 phosphorylation in ARC POMC neurons, and thereby ameliorates hyperphagia and obesity caused by leptin deficiency. IL-10 gene transfer may provide an effective approach for preventing progression of metabolic syndrome due to leptin resistance.


Arcuate Nucleus of Hypothalamus/metabolism , Diabetes Mellitus/pathology , Hyperphagia/pathology , Interleukin-10/metabolism , Obesity/pathology , Pro-Opiomelanocortin/metabolism , Animals , Disease Models, Animal , Energy Metabolism , Gene Transfer Techniques , Leptin , Male , Mice , Up-Regulation
9.
Mol Psychiatry ; 21(1): 39-48, 2016 Jan.
Article En | MEDLINE | ID: mdl-26481320

Depression is a common debilitating human disease whose etiology has defied decades of research. A critical bottleneck is the difficulty in modeling depressive episodes in animals. Here, we show that a transgenic mouse with chronic forebrain expression of a dominant negative mutant of Polg1, a mitochondrial DNA (mtDNA) polymerase, exhibits lethargic behavioral changes, which are associated with emotional, vegetative and psychomotor disturbances, and response to antidepression drug treatment. The results suggested a symptomatic similarity between the lethargic behavioral change that was recurrently and spontaneously experienced by the mutant mice and major depressive episode as defined by DSM-5. A comprehensive screen of mutant brain revealed a hotspot for mtDNA deletions and mitochondrial dysfunction in the paraventricular thalamic nucleus (PVT) with similar defects observed in postmortem brains of patients with mitochondrial disease with mood symptoms. Remarkably, the genetic inhibition of PVT synaptic output by Cre-loxP-dependent expression of tetanus toxin triggered de novo depression-like episodes. These findings identify a novel preclinical mouse model and brain area for major depressive episodes with mitochondrial dysfunction as its cellular mechanism.


DNA-Directed DNA Polymerase/metabolism , Depressive Disorder/physiopathology , Midline Thalamic Nuclei/metabolism , Animals , Comorbidity , Corticosterone/analysis , DNA Polymerase gamma , DNA-Directed DNA Polymerase/genetics , Depressive Disorder/complications , Depressive Disorder/genetics , Depressive Disorder/pathology , Disease Models, Animal , Feces/chemistry , Female , Humans , Immunohistochemistry , Male , Mice, Transgenic , Midline Thalamic Nuclei/pathology , Mitochondria/metabolism , Motor Activity/physiology , Mutation , Neurons/metabolism , Ophthalmoplegia, Chronic Progressive External/complications , Ophthalmoplegia, Chronic Progressive External/metabolism , Ophthalmoplegia, Chronic Progressive External/pathology
10.
Clin Exp Immunol ; 184(1): 126-36, 2016 Apr.
Article En | MEDLINE | ID: mdl-26560892

Our previous work revealed that the recipients with the highest pre-existing numbers of CD8(+) effector T cells (TE ) [hyperparathyroidism (HPT)E recipients] occupied approximately 30% of adult transplant recipients performed in our hospital. HPTE recipients demonstrated very poor clinical outcome compared with the remaining 70% of recipients with the lowest pre-existing TE (LPTE recipient). This study aimed to clarify the best combined immunosuppressive regimen related to function of cytotoxic T lymphocytes (CTLs) for HPTE recipients. Eighty-one HPTE recipients were classified into three types, according to the immunosuppressive regimens: type 1, tacrolimus (Tac)/glucocorticoid (GC); type 2, Tac/mycophenolate mofetil (MMF)/GC; and type 3, Tac/MMF. Frequencies of severe infection, rejection and hospital death were the highest in types 1 and 2, whereas the lowest occurred in type 3. The survival rate in type 3 was the highest (100%) during follow-up until post-operative day 2000. Regarding the immunological mechanism, in type 1 TE perforin and interferon (IFN)-γ were generated through the self-renewal of CD8(+) central memory T cells (TCM ), but decreased in the early post-transplant period due to marked down-regulation of interleukin (IL)-12 receptor beta-1 of TCM. In type 2, the self-renewal TCM did not develop, and the effector function could not be increased. In type 3, in contrast, the effectors and cytotoxicity were correlated inversely with IL-12Rß1(+) TCM levels, and increased at the highest level around the pre-transplant levels of IL-12Rß1(+) TCM . However, the immunological advantage of Tac/MMF therapy was inhibited strongly by additive steroid administration.


Graft Rejection/prevention & control , Immunosuppressive Agents/therapeutic use , Liver Transplantation , Methylprednisolone/adverse effects , Mycophenolic Acid/analogs & derivatives , T-Lymphocytes, Cytotoxic/drug effects , Tacrolimus/therapeutic use , Aged , Female , Gene Expression , Graft Rejection/immunology , Graft Rejection/mortality , Graft Rejection/pathology , Graft Survival , Humans , Hyperparathyroidism/immunology , Hyperparathyroidism/mortality , Hyperparathyroidism/pathology , Hyperparathyroidism/surgery , Immunologic Memory , Interferon-gamma/genetics , Interferon-gamma/immunology , Living Donors , Male , Middle Aged , Mycophenolic Acid/therapeutic use , Perforin/genetics , Perforin/immunology , Receptors, Interleukin-12/genetics , Receptors, Interleukin-12/immunology , Retrospective Studies , Survival Analysis , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/pathology , Unrelated Donors
11.
J Thromb Haemost ; 13 Suppl 1: S133-42, 2015 Jun.
Article En | MEDLINE | ID: mdl-26149014

Hemophilia is considered suitable for gene therapy because it is caused by a single gene abnormality, and therapeutic coagulation factor levels may vary across a broad range. Recent success of hemophilia B gene therapy with an adeno-associated virus (AAV) vector in a clinical trial showed the real prospect that, through gene therapy, a cure for hemophilia may become a reality. However, AAV-mediated gene therapy is not applicable to patients with hemophilia A at present, and neutralizing antibodies against AAV reduce the efficacy of AAV-mediated strategies. Because patients that benefit from AAV treatment (hemophilia B without neutralizing antibodies) are estimated to represent only 15% of total patients with hemophilia, the development of basic technologies for hemophilia A and those that result in higher therapeutic effects are critical. In this review, we present an outline of gene therapy methods for hemophilia, including the transition of technical developments thus far and our novel techniques.


Genetic Therapy/methods , Hemophilia A/therapy , Hemorrhage/therapy , Animals , Blood Coagulation/genetics , Dependovirus/genetics , Gene Transfer Techniques , Genetic Predisposition to Disease , Genetic Vectors , Hemophilia A/blood , Hemophilia A/diagnosis , Hemophilia A/genetics , Hemorrhage/blood , Hemorrhage/diagnosis , Hemorrhage/genetics , Humans , Phenotype
12.
Clin Exp Immunol ; 181(2): 373-84, 2015 Aug.
Article En | MEDLINE | ID: mdl-25603847

This study aimed to investigate the role of initial priming of interleukin (IL)-12 receptor beta-1 in CD8(+) central memory T cells (initial IL-12RTCM priming) and CCR7-negative subsets (CNS) in effector cell expansion and clinical outcome after living donor liver transplantation (LDLT). One hundred and six patients who underwent LDLT were classified into the following three groups according to hierarchical clustering of CD8(+) CD45 isoforms before LDLT: I, naive-dominant; II, effector memory-dominant; and III, effector-dominant. The pre-existing CD8(+) effector cells (TE ) and activated immune status increased progressively from group I to group II to group III. Groups I, II and III received tacrolimus (Tac)/glucocorticoid (GC) regimens. Eighteen group III recipients received Tac/mycophenolate mofetil (MMF) and were defined as group IV. Initial IL-12RTCM priming was slightly, moderately and markedly decreased in droups I, II, and III, respectively. Initial priming of IL-12Rß1 in CNS was decreased markedly in the three groups with marked decreases of TE , perforin and interferon (IFN)-γ; all parameters were restored by up-regulation of IL-12Rß1(+) TCM through the self-renewal of TCM . The lag time required until coupled up-regulation of IL-12Rß1 of TCM and CNS to above baseline was 12, 20 and 32 days in groups I, II and III, respectively. Inferior clinical outcomes were associated with increasing lag time. In contrast, the initial priming of IL-12Rß1 in TCM and CNS remained above baseline in group IV due to MMF-mediated increase of IL-12Rß1. Early coupled up-regulation of TCM and CNS leads to efficient TE differentiation and optimal clinical outcomes.


CD8 Antigens/immunology , Immunosuppressive Agents/therapeutic use , Liver Transplantation , Receptors, Interleukin-12/immunology , T-Lymphocytes, Cytotoxic/immunology , Tacrolimus/therapeutic use , Adult , CD8 Antigens/genetics , Cell Differentiation/drug effects , Female , Gene Expression , Glucocorticoids/therapeutic use , Humans , Immunologic Memory/drug effects , Interferon-gamma/biosynthesis , Interferon-gamma/immunology , Leukocyte Common Antigens/genetics , Leukocyte Common Antigens/immunology , Liver/immunology , Liver/pathology , Liver/surgery , Living Donors , Male , Middle Aged , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Perforin/genetics , Perforin/immunology , Receptors, CCR7/deficiency , Receptors, CCR7/genetics , Receptors, CCR7/immunology , Receptors, Interleukin-12/agonists , Receptors, Interleukin-12/genetics , T-Lymphocytes, Cytotoxic/drug effects , Time Factors , Transplant Recipients , Treatment Outcome , Up-Regulation
13.
Gene Ther ; 22(2): 209-15, 2015 Feb.
Article En | MEDLINE | ID: mdl-25427612

Engineered T-cell therapy using a CD19-specific chimeric antigen receptor (CD19-CAR) is a promising strategy for the treatment of advanced B-cell malignancies. Gene transfer of CARs to T-cells has widely relied on retroviral vectors, but transposon-based gene transfer has recently emerged as a suitable nonviral method to mediate stable transgene expression. The advantages of transposon vectors compared with viral vectors include their simplicity and cost-effectiveness. We used the Tol2 transposon system to stably transfer CD19-CAR into human T-cells. Normal human peripheral blood lymphocytes were co-nucleofected with the Tol2 transposon donor plasmid carrying CD19-CAR and the transposase expression plasmid and were selectively propagated on NIH3T3 cells expressing human CD19. Expanded CD3(+) T-cells with stable and high-level transgene expression (~95%) produced interferon-γ upon stimulation with CD19 and specifically lysed Raji cells, a CD19(+) human B-cell lymphoma cell line. Adoptive transfer of these T-cells suppressed tumor progression in Raji tumor-bearing Rag2(-/-)γc(-/-) immunodeficient mice compared with control mice. These results demonstrate that the Tol2 transposon system could be used to express CD19-CAR in genetically engineered T-cells for the treatment of refractory B-cell malignancies.


Antigens, CD19/immunology , DNA Transposable Elements , Lymphoma, B-Cell/therapy , Receptors, Antigen, T-Cell/genetics , T-Lymphocytes/immunology , Animals , Cell Line, Tumor , Coculture Techniques , Genetic Engineering , Genetic Therapy , Humans , Immunotherapy, Adoptive , Mice , Mice, Inbred BALB C , Mice, Knockout , Molecular Sequence Data , NIH 3T3 Cells , Neoplasm Transplantation , Receptors, Antigen, T-Cell/biosynthesis , Recombinant Fusion Proteins/biosynthesis , Recombinant Fusion Proteins/genetics
14.
Haemophilia ; 20(1): e40-4, 2014 Jan.
Article En | MEDLINE | ID: mdl-24354485

The use of induced pluripotent stem cells (iPSCs) as an autologous cell source has shed new light on cell replacement therapy with respect to the treatment of numerous hereditary disorders. We focused on the use of iPSCs for cell-based therapy of haemophilia. We generated iPSCs from mesenchymal stem cells that had been isolated from C57BL/6 mice. The mouse iPSCs were generated through the induction of four transcription factor genes Oct3/4, Klf-4, Sox-2 and c-Myc. The derived iPSCs released functional coagulation factor VIII (FVIII) following transduction with a simian immunodeficiency virus vector. The subcutaneous transplantation of iPSCs expressing FVIII into nude mice resulted in teratoma formation, and significantly increased plasma levels of FVIII. The plasma concentration of FVIII was at levels appropriate for human therapy at 2-4 weeks post transplantation. Our data suggest that iPSCs could be an attractive and prospective autologous cell source for the production of coagulation factor, and that engineered iPSCs expressing coagulation factor might provide a cell-based therapeutic strategy appropriate for haemophilia.


Factor VIII/biosynthesis , Factor VIII/genetics , Genetic Vectors/genetics , Induced Pluripotent Stem Cells/metabolism , Simian Immunodeficiency Virus/genetics , Animals , Cell Differentiation , Cells, Cultured , Gene Expression , Gene Order , Induced Pluripotent Stem Cells/cytology , Mesenchymal Stem Cells/cytology , Mice , Time Factors , Transduction, Genetic
16.
Article En | MEDLINE | ID: mdl-23239931

We report a patient with primary anti-phospholipid syndrome (APS) who developed pulmonary edema following sudden-onset pain in the left, lower back of the chest. Radiological examinations demonstrated fresh infarction of the left adrenal gland but no obvious thrombi in pulmonary arteries. The patient quickly recovered from pulmonary edema with anti-coagulation therapy alone. Primary APS may have caused adrenal infarction in the patient, leading to transient pulmonary edema via microthrombosis and/or excessive release of catecholamine.

17.
Phys Rev Lett ; 109(13): 132002, 2012 Sep 28.
Article En | MEDLINE | ID: mdl-23030084

The Θ(+) pentaquark baryon was searched for via the π(-)p→K(-)X reaction with a missing mass resolution of 1.4 MeV/c(2) (FWHM) at the Japan Proton Accelerator Research Complex (J-PARC). π(-) meson beams were incident on the liquid hydrogen target with a beam momentum of 1.92 GeV/c. No peak structure corresponding to the Θ(+) mass was observed. The upper limit of the production cross section averaged over the scattering angle of 2° to 15° in the laboratory frame is obtained to be 0.26 µb/sr in the mass region of 1.51-1.55 GeV/c(2). The upper limit of the Θ(+) decay width is obtained to be 0.72 and 3.1 MeV for J(Θ)(P)=1/2(+) and J(Θ)(P)=1/2(-), respectively, using the effective Lagrangian approach.

18.
J Thromb Haemost ; 10(9): 1802-13, 2012 Sep.
Article En | MEDLINE | ID: mdl-22784361

BACKGROUND: Transplantation of cells overexpressing a target protein represents a viable gene therapeutic approach for treating hemophilia. Here, we focused on the use of autologous mesenchymal stem cells (MSCs) expressing coagulation factor for the treatment of coagulation factor VIII (FVIII) deficiency in mice. METHODS AND RESULTS: Analysis of luciferase gene constructs driven by different promoters revealed that the plasminogen activator inhibitor-1 (PAI-1) gene promoter coupled with the cytomegalovirus promoter enhancer region was one of the most effective promoters for producing the target protein. MSCs transduced with the simian immunodeficiency virus (SIV) vector containing the FVIII gene driven by the PAI-1 promoter expressed FVIII for several months, and this expression was maintained after multiple mesenchymal lineage differentiation. Although intravenous injection of cell supernatant derived from MSCs transduced with an SIV vector containing the FVIII gene driven by the PAI-1 promoter significantly increased plasma FVIII levels, subcutaneous implantation of the MSCs resulted in a transient and weak increase in plasma FVIII levels in FVIII-deficient mice. Interestingly, intra-articular injection of the transduced MSCs significantly ameliorated the hemarthrosis and hemophilic arthropathy induced by knee joint needle puncture in FVIII-deficient mice. The therapeutic effects of a single intra-articular injection of transduced MSCs to inhibit joint bleeding persisted for at least 8 weeks after administration. CONCLUSIONS: MSCs provide a promising autologous cell source for the production of coagulation factor. Intra-articular injection of MSCs expressing coagulation factor may offer an attractive treatment approach for hemophilic arthropathy.


Blood Coagulation Factors/metabolism , Cell Transplantation , Factor VIII/genetics , Hemophilia A/therapy , Joint Diseases/therapy , Mesenchymal Stem Cells/cytology , Animals , Hemophilia A/complications , Injections, Intra-Articular , Joint Diseases/complications , Mesenchymal Stem Cells/metabolism , Mice , Plasminogen Activator Inhibitor 1/genetics , Promoter Regions, Genetic
19.
J Nanosci Nanotechnol ; 12(2): 1238-41, 2012 Feb.
Article En | MEDLINE | ID: mdl-22629929

The single phase ErFe(x)Mn1-xO3 (0 < or = x < or = 0.15) compounds were synthesized by the solid-state reaction method. The doping effects on the crystal structural, magnetic, thermal, and dielectric properties were systematically investigated. The XRD patterns show all samples crystallize in the hexagonal structure with P6(3)cm space group. The lattice parameters a and c first decrease with doping, which is followed by a subsequent increase at higher doping levels. Although both the Fe3+ and Mn3+ ions remain stable in high spin trivalent states in all samples, the magnetization is weakened with increasing Fe contents. The heat capacity data shows the antiferromagnetic transition slightly shifts from 77 K for ErMnO3 to 80 K for ErFe015Mn0.85O3, which can not be observed in the magnetic susceptibility data. The real part of complex impedance of these samples rises as the doping level increases, indicating the enhancement of insulativity of doped samples.

20.
Phys Rev Lett ; 108(11): 116802, 2012 Mar 16.
Article En | MEDLINE | ID: mdl-22540498

Surface metallization of SrTiO3(001) by hydrogen adsorption is experimentally confirmed for the first time by photoemission spectroscopy and surface conductivity measurements. The metallic state is assigned to a quantized state in the space-charge layer induced by electron doping from hydrogen atoms. The measured two-dimensional (2D) conductivity is well above the 2D Ioffe-Regel limit indicating that the system is in a metallic conduction regime. The mean free path of the surface electron is estimated to be several nanometers at room temperature.

...